Brodalumab is an anti-IL 17 receptor MAB, which I think is a dead end in
rheumatoid arthritis but a promising new drug on the horizon against psoriatic
arthritis as it targets IL-17, which plays a role
"in the pathogenesis and ongoing inflammation of psoriatic disease".
Out of the three abstracts/posters on brodalumab, two are of interest for us.
P.J. Mease and colleagues presented the following study [SAT0404]:
"FIFTY-TWO WEEK CLINICAL RESPONSE TO BRODALUMAB, AN ANTI-IL-17R ANTIBODY, IN
SUBJECTS WITH PSORIATIC ARTHRITIS". Conclusions: "Brodalumab
treatment was associated with improvements in musculoskeletal and skin symptoms
in subjects with PsA. Clinical responses were sustained through week 52. These
results support continued evaluation of brodalumab for treatment of PsA."
I know, it's a phase 2 study and more shouldn't be expected.
M.C. Genovese and colleagues presented [AB0752]:
"EFFICACY AND SAFETY OF BRODALUMAB OVER ONE YEAR IN PATIENTS WITH PSORIATIC
ARTHRITIS WITH AND WITHOUT PRIOR EXPOSURE TO A BIOLOGIC". Conclusions:
"Prior exposure to a biologic does not seem to affect the efficacy or
tolerability of brodalumab over one year in the treatment of PsA." Good to
hear as we might try after approval to treat patients with failures to
TNF-inhibitors and/or failure to ustekinumab.
Brodalumab is promising in psoriatic arthritis, but still has a long way
to go, which means for us: we have to wait. I won't expect approval within the
next two years.
Link:
No comments:
Post a Comment